For nearly a decade, Solid has been a staunch supporter and a steering committee member of Parent Project Muscular Dystrophy’s (PPMD) committee dedicated to implementing newborn screening for Duchenne ...
Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...
Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...
Scotland’s NHS can now offer givinostat to ambulant children with Duchenne muscular dystrophy, marking a step forward in care ...
A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.
A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...
Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people.
Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the ...
Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...
This article has been revised and clarified. Pasadena-based biopharma company Arrowhead Pharmaceuticals Inc. had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback